Health Condition 1: A150- Tuberculosis of lung
Conditions
Interventions
Intervention1: Urine isoniazid testing: At routine monthly clinic visits during TB treatment and during unannounced home visits, the researchers will assess medication adherence using the Isoscreen te
Sponsors
ICMR National Institute for Research in Tuberculosis
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria will be: (a) 18+ years of age, (b) presumed or confirmed drug-susceptible pulmonary TB (with or without a previous TB history), and (c) taking an isoniazid-containing TB regimen.
Exclusion criteria
Exclusion criteria: Exclusion criteria will include: (a) inability to provide informed consent, and (b) drug-resistant TB diagnosis or switch to another non-isoniazid-containing regimen. As drug-resistant TB diagnosis or regimen switches occur weeks into therapy, these will result in retrospective exclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite of: (1) loss to follow-up during TB treatment, (2) TB treatment failure, death during the on-treatment or post-treatment period, and (4) TB recurrence.Timepoint: Outcomes will be assessed during TB treatment and during 12 months of follow-up after completion of TB treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Each of the following individual outcomes will be evaluated alone as a secondary outcome: (1) loss to follow-up during TB treatment, (2) TB treatment failure, (3) death during the on-treatment or post-treatment period, (4) TB recurrenceTimepoint: Outcomes will be assessed during TB treatment and during the 12 months of follow-up after completion of TB treatment | — |
Countries
India
Contacts
Public ContactDr Karikalan Nagarajan
ICMR National Institute for Research in Tuberculosis
Outcome results
None listed